Wellcome Trust – the second largest charitable foundation in the world and co-founder of Human Genome Project – has made drug-resistant infections one of its strategic priorities and plans to use its political independence and financial power to maintain momentum built by the UK's O'Neill AMR Review, which it co-funded, according to the trust's policy head Ed Whiting.
Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.
More from R&D
• By
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The chair of a European Medicines Agency working group on reducing animal testing said that companies can provide “thoughts and suggestions” in relation to a review of its scientific guidelines on regulatory testing requirements and new approach methodologies.
• By
Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.
More from Pink Sheet
• By
Israel has introduced a new framework to expedite the marketing approval of medicines, make the country a more attractive destination for drug registration and help reduce drug prices through market competition.
• By
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
• By
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth